



PCT 143 03 1001237



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

SEC'D 16 MAY 2003


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Stephen Hordley

Dated 15 April 2003

BEST AVAILABLE COPY

The Patent Office


1/77

Request for grant of a patent

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
 Newport
 Gwent NP9 1RH



Your reference

T1571PV

Patent application number
 (The Patent Office will fill in this part)

020/139.7

27MAR02 E706802-1 002639
 P01/7700 0.00-0207139.7

Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited
 Hertford Road, Hoddesdon
 Hertfordshire EN11 9BU
 United Kingdom

Patents ADP number (if you know it)

00597799001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

Title of the invention

Novel pharmaceutical agent

Name of your agent (if you have one)

Dr. J. Thompson

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Merck & Co., Inc.
 European Patent Department
 Terlings Park
 Eastwick Road
 Harlow
 Essex CM20 2QR

Patents ADP number (if you know it)

4392742002

If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number
 (if you know it)

Date of filing
 (day/month/year)

If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
 (day/month/year)

Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

BEST AVAILABLE COPY


NOVEL THERAPEUTIC TREATMENT

This invention relates to the use of a particular heteroaromatic compound. More particularly, the invention is concerned with the use of a (1,2,3,6-tetrahydropyridin-1-yl)methyl substituted benzofuran derivative which is a selective antagonist of the D₄ dopamine receptor subtype within the brain and is therefore of benefit in the treatment and/or prevention of attention-deficit/hyperactivity disorder (ADHD).

ADHD is a condition characterised by inattentive, impulsive hyperactive behaviour, and affects some 6% of school age boys in the USA. Although primarily affecting children, in some cases the symptoms persist into adulthood. Several recent studies have implicated the dopamine D₄ receptor in the etiology of ADHD (see, for example, Zhang et al, *Neuropsychopharmacology*, 25, 624-632, 2001 and references therein).

US Patent No. 5,665,722 discloses a class of substituted benzofuran derivatives which are selective dopamine D₄ antagonists and which are said to be useful in the treatment of schizophrenia.

According to the present invention, there is provided a method of treating or preventing ADHD comprising administering to a subject in need thereof a therapeutically-effective amount of the compound of formula I:



or a pharmaceutically acceptable salt thereof.

In one embodiment of the invention, the subject is a human male. In this embodiment, the subject is typically a human male aged 5-18 years, preferably aged 12-18 years.

BEST AVAILABLE COPY

The method of treatment according to the invention typically comprises administering to the subject a tablet containing from 1 to 100 mg of the compound of formula I or pharmaceutically acceptable salt thereof once, twice, three times or four times a day. Preferably, the tablet contains from 2 to 50 mg, more preferably from 5 to 25 mg, of the compound of formula I or pharmaceutically acceptable salt thereof, and is administered once or twice a day. In a particular embodiment, a tablet containing 15 mg of the compound of formula I or pharmaceutically acceptable salt thereof is administered once a day.

The method of treatment according to the invention may be used for treatment of ADHD which is of the combined type, or which is of the predominantly inattentive type, or which is of the predominantly hyperactive-impulsive type.

There is further disclosed the use of the compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treatment or prevention of ADHD.

For use in medicine, the salts of the compound of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compound of use in the invention or of its pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compound of use in this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound of use in the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, methanesulphonic acid, carbonic acid or phosphoric acid. Examples of preferred salts include the methanesulphonate (mesylate) salt.

The medicaments relevant to the invention are typically pharmaceutical compositions comprising the compound of formula I, or pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier. Preferably these compositions are in

unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the compound of formula I, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active

ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 15, 25, 50 or 100 mg, of the active ingredient. The tablets or pills can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of

materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

5 The liquid forms in which the compositions relevant to the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for
10 aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of ADHD, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and
15 especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

In order to alleviate the symptoms of ADHD without causing
sedation or extrapyramidal side-effects, the dosage level of the compound of formula I may be selected such that the dose administered is effective in
20 substantially completely blocking the dopamine D₄ receptor subtype in human brain whilst displaying no or negligible dopamine D₂ receptor subtype occupancy. A suitable dosage level in this regard is about 0.001 to 5.0 mg/kg per day, more particularly about 0.005 to 1.0 mg/kg per day, and especially about 0.01 to 0.5 mg/kg per day.

25

EXAMPLE 1

Use of the compound of formula I for treatment of ADHD

The mesylate salt of the compound of formula I is prepared as described in Example 1 of GB 2,306,471. Tablets comprising 15 mg of this
30 active ingredient are prepared by conventional means and a single tablet is administered once a day to a subject suffering from, or prone to ADHD.

BEST AVAILABLE COPY